B

Bavarian Nordic A/S
OTC:BVNRY

Watchlist Manager
Bavarian Nordic A/S
OTC:BVNRY
Watchlist
Price: 10.43 USD -0.01% Market Closed
Market Cap: $2.4B

Operating Margin

36.2%
Current
Improving
by 17%
vs 3-y average of 19.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
36.2%
=
Operating Income
kr2.5B
/
Revenue
kr6.9B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
36.2%
=
Operating Income
$2.5B
/
Revenue
kr6.9B

Peer Comparison

Country Company Market Cap Operating
Margin
DK
Bavarian Nordic A/S
CSE:BAVA
15.5B DKK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Higher than 90% of companies in Denmark
Percentile
90th
Based on 506 companies
90th percentile
36.2%
Low
-5 981.6% — 1.3%
Typical Range
1.3% — 16.3%
High
16.3% — 423.3%
Distribution Statistics
Denmark
Min -5 981.6%
30th Percentile 1.3%
Median 7.5%
70th Percentile 16.3%
Max 423.3%

Bavarian Nordic A/S
Glance View

Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.

BVNRY Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
36.2%
=
Operating Income
kr2.5B
/
Revenue
kr6.9B
What is Bavarian Nordic A/S's current Operating Margin?

The current Operating Margin for Bavarian Nordic A/S is 36.2%, which is above its 3-year median of 19.2%.

How has Operating Margin changed over time?

Over the last 3 years, Bavarian Nordic A/S’s Operating Margin has increased from -14.7% to 36.2%. During this period, it reached a low of -14.7% on Aug 30, 2022 and a high of 36.2% on Oct 30, 2025.

Back to Top